

## Product Update:

zonisamide 25mg, 50mg and 100mg capsules (Zonegran®) (No: 949/14)  
Eisai Limited

07 February 2014

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**zonisamide (Zonegran®)** is accepted for restricted use within NHS Scotland.

**Indication under review:** as adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adolescents, and children aged 6 years and above.

**SMC restriction:** on advice from specialists (paediatric neurologists or paediatricians with an expertise in epilepsy).

The Scottish Medicines Consortium has previously accepted zonisamide for restricted use in adult patients with partial seizures, with or without secondary generalisation. It was restricted to initiation by physicians with appropriate experience in the treatment of epilepsy and should be used principally in patients who have not benefited from treatment with an older anti-convulsant drug such as carbamazepine or sodium valproate, or for whom these drugs are unsuitable because of contra-indications, interaction or poor tolerance.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 05 December 2013.*

**Chairman**  
**Scottish Medicines Consortium**

Published 10 March 2014